Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo.
about
Loss of a 20S proteasome activator in Saccharomyces cerevisiae downregulates genes important for genomic integrity, increases DNA damage, and selectively sensitizes cells to agents with diverse mechanisms of actionMechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone RemodelingIdentification of nitric oxide as an endogenous inhibitor of 26S proteasomes in vascular endothelial cells.MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells.Osteoblastogenesis and tumor growth in myeloma.Advances in the understanding of myeloma bone disease and tumour growth.A mathematical model of bone remodeling dynamics for normal bone cell populations and myeloma bone disease.A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genesRegulation of the proteasome by AMPK in endothelial cells: the role of O-GlcNAc transferase (OGT).Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib.Myeloma cell-derived Runx2 promotes myeloma progression in bone.Enhancement of 26S proteasome functionality connects oxidative stress and vascular endothelial inflammatory response in diabetes mellitus.Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markersThe epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.Effects of proteasome inhibitors on bone cancerOncolytic vesicular stomatitis virus and bortezomib are antagonistic against myeloma cells in vitro but have additive anti-myeloma activity in vivo.Negatively charged metal oxide nanoparticles interact with the 20S proteasome and differentially modulate its biologic functional effects.Parathyroid hormone receptor mediates the anti-myeloma effect of proteasome inhibitors.Tumor-host cell interactions in the bone disease of myeloma.Bone marker gene expression in calvarial bones: different bone microenvironments.Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress.Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin Lymphoma.Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization.Inhibition of the Proteasome β2 Site Sensitizes Triple-Negative Breast Cancer Cells to β5 Inhibitors and Suppresses Nrf1 Activation.
P2860
Q27930325-9C45F110-4AAE-4A92-903E-F77EBEC930FDQ28082335-01C08B79-CFEB-4BA4-BCB9-82713295C353Q33650608-5174ECA4-F078-4C5C-84AD-25317BA2DDCDQ33714747-D279209C-7CE6-4769-9263-01E4BA997C90Q33768466-95B2A6A2-1D20-4618-A5D7-A306746DBBD6Q33829022-005801FB-2960-4053-B484-279ACB00A2CEQ33843095-4D8692B1-94B6-45EC-960D-FB5DCBA348D7Q34203659-303AE5A9-DB30-43C9-9E34-D38AF9296643Q34264918-A0BF079A-8FD4-4C94-9137-F9FF8D38890EQ34608271-AE5B9A86-34FB-40E7-895D-CA54315EFC7DQ35692401-ABA7035B-B4B3-4BEB-B36A-AADE5F594B01Q36204680-DB7EF353-8BA5-4E1D-8FE6-58FDE1E3D06DQ36665156-3B417136-2A17-4CF5-97E4-F8724504427FQ37166798-D6B40AD4-00E8-4741-99E9-CA3FFA5DFB04Q37281071-6764C30E-D7F0-4563-AB2A-99A3907BA6EBQ37381298-7EE87BDF-5EDF-47EF-8327-6F58E0E52877Q37624470-DEFA94E8-BA2F-4C90-A71C-AB15056728DAQ37668104-3EF6361E-7898-4898-8208-17FE5FD2789FQ37771082-DF1674CB-580E-450B-A00F-AE55EEBB99EBQ38775716-83342DED-8A40-4DFF-8B19-2942D534B8A8Q41279386-8C8F9E17-C40D-4F1E-8F2C-4EE2274F3DB1Q42320787-D5BE4853-B874-4B8D-83F4-43E3104E4FC8Q43753506-6693DCBE-6576-4177-B6A2-112E152DD6F6Q47987649-F6A0D4E1-8D36-4D8D-9968-DE4CD6A478E6
P2860
Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Myeloma cells exhibit an incre ...... rrow microenvironment in vivo.
@en
Myeloma cells exhibit an incre ...... rrow microenvironment in vivo.
@nl
type
label
Myeloma cells exhibit an incre ...... rrow microenvironment in vivo.
@en
Myeloma cells exhibit an incre ...... rrow microenvironment in vivo.
@nl
prefLabel
Myeloma cells exhibit an incre ...... rrow microenvironment in vivo.
@en
Myeloma cells exhibit an incre ...... rrow microenvironment in vivo.
@nl
P2093
P2860
P356
P1476
Myeloma cells exhibit an incre ...... arrow microenvironment in vivo
@en
P2093
Andreia L Bates
Babatunde O Oyajobi
Gregory R Mundy
Jessica A Fowler
Junling Zhuang
Seint T Lwin
P2860
P304
P356
10.1002/AJH.21374
P577
2009-05-01T00:00:00Z